# United States Medicare Begins Covering Obesity Drugs for the First Time

A new program starting July 1 opens access to weight-loss medicines for millions of older Americans, expanding the market for Novo Nordisk and Eli Lilly.

- Published: 2026-06-30T10:17:56.546Z
- Canonical: https://polylog.news/2026-06-30/united-states-medicare-begins-covering-obesity-drugs-for-the
- Publisher: Polylog (Global desk)
- Section: markets
- Sources: [CNBC](https://www.cnbc.com/2026/06/30/medicare-obesity-drug-glp-1-coverage-starting-july-1.html), [CNN](https://www.cnn.com/2026/06/29/health/medicare-glp1-coverage)

The United States Medicare program, which covers older and disabled Americans, will begin covering obesity medicines on July 1 for the first time, under a demonstration program that runs through the end of 2027, according to CNBC. Eligible beneficiaries will be able to obtain glucagon-like peptide-1 (GLP-1) drugs, the class of weight-loss medicines that includes Novo Nordisk's Wegovy and Eli Lilly's Zepbound, for a [copay of about 50 dollars a month](https://www.cnbc.com/2026/06/30/medicare-obesity-drug-glp-1-coverage-starting-july-1.html).

Under the arrangement, which stems from a deal the Trump administration announced with the two drugmakers, the government will pay about 245 dollars for a month's supply. The Kaiser Family Foundation estimates that about [3.8 million beneficiaries](https://www.cnn.com/2026/06/29/health/medicare-glp1-coverage), roughly 8 percent of the relevant enrollees, could be eligible.

The change could bring in millions of new patients for the manufacturers while adding a significant new cost to a public program. Physicians have warned that prior-authorization requirements and a sharp rise in demand could strain clinics and pharmacies.

## What this means

Public insurance coverage transforms obesity drugs from a cash-payment product into a mass market, a major revenue expansion for Novo Nordisk and Eli Lilly and a meaningful new area of federal spending. How the demonstration is priced and rationed will shape both the companies' growth and the public cost of a rapidly growing category in medicine.

## What to watch

- Take-up rates among eligible Medicare beneficiaries, the figure that determines both company revenue and program cost.
- Whether the negotiated price holds or shifts as volumes rise, a test of the government's leverage with the drugmakers.
- Supply and manufacturing capacity at Novo Nordisk and Eli Lilly, since demand could exceed production.